209 related articles for article (PubMed ID: 18288089)
21. Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal.
Zhou Y; Spangler R; Schlussman SD; Ho A; Kreek MJ
Brain Res; 2003 Feb; 964(2):187-99. PubMed ID: 12576179
[TBL] [Abstract][Full Text] [Related]
22. Role of corticotropin-releasing factor and corticosterone in behavioral sensitization to ethanol.
Pastor R; Reed C; Meyer PJ; McKinnon C; Ryabinin AE; Phillips TJ
J Pharmacol Exp Ther; 2012 May; 341(2):455-63. PubMed ID: 22333290
[TBL] [Abstract][Full Text] [Related]
23. Noradrenergic and corticosteroid receptors regulate somatic and motivational symptoms of morphine withdrawal.
Solecki WB; Kus N; Gralec K; Klasa A; Pradel K; Przewłocki R
Behav Brain Res; 2019 Mar; 360():146-157. PubMed ID: 30500430
[TBL] [Abstract][Full Text] [Related]
24. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence.
Lu L; Liu D; Ceng X; Ma L
Eur J Neurosci; 2000 Dec; 12(12):4398-404. PubMed ID: 11122350
[TBL] [Abstract][Full Text] [Related]
25. Galanin negatively modulates opiate withdrawal via galanin receptor 1.
Holmes FE; Armenaki A; Iismaa TP; Einstein EB; Shine J; Picciotto MR; Wynick D; Zachariou V
Psychopharmacology (Berl); 2012 Apr; 220(3):619-25. PubMed ID: 21969124
[TBL] [Abstract][Full Text] [Related]
26. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis.
Alcaraz C; Vargas ML; Milanés MV
Neuropeptides; 1996 Feb; 30(1):29-36. PubMed ID: 8868296
[TBL] [Abstract][Full Text] [Related]
27. Role of withdrawal in reinstatement of morphine-conditioned place preference.
Lu L; Chen H; Su W; Ge X; Yue W; Su F; Ma L
Psychopharmacology (Berl); 2005 Aug; 181(1):90-100. PubMed ID: 15739075
[TBL] [Abstract][Full Text] [Related]
28. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: implications for a role for CRF in the pathogenesis of anxiety disorders.
Owens MJ; Vargas MA; Nemeroff CB
J Psychiatr Res; 1993; 27 Suppl 1():209-20. PubMed ID: 8145178
[TBL] [Abstract][Full Text] [Related]
29. Restricted role of CRF1 receptor for the activity of brainstem catecholaminergic neurons in the negative state of morphine withdrawal.
Garcia-Carmona JA; Almela P; Baroja-Mazo A; Milanes MV; Laorden ML
Psychopharmacology (Berl); 2012 Mar; 220(2):379-93. PubMed ID: 21947312
[TBL] [Abstract][Full Text] [Related]
30. Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal.
Navarro-Zaragoza J; Núñez C; Laorden ML; Milanés MV
Mol Pharmacol; 2010 May; 77(5):864-73. PubMed ID: 20159948
[TBL] [Abstract][Full Text] [Related]
31. The involvement of CRF1 receptor within the basolateral amygdala and dentate gyrus in the naloxone-induced conditioned place aversion in morphine-dependent mice.
Valero E; Gómez-Milanés I; Almela P; Ribeiro Do Couto B; Laorden ML; Milanés MV; Núñez C
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):102-114. PubMed ID: 29407532
[TBL] [Abstract][Full Text] [Related]
32. Morphine withdrawal activates hypothalamic-pituitary-adrenal axis and heat shock protein 27 in the left ventricle: the role of extracellular signal-regulated kinase.
Martínez-Laorden E; Hurle MA; Milanés MV; Laorden ML; Almela P
J Pharmacol Exp Ther; 2012 Sep; 342(3):665-75. PubMed ID: 22647273
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
34. Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system.
Funada M; Hara C; Wada K
Eur J Pharmacol; 2001 Nov; 430(2-3):277-81. PubMed ID: 11711043
[TBL] [Abstract][Full Text] [Related]
35. The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury.
Kosari-Nasab M; Sadeghi T; Bashiri H; Shokouhi G; Salari AA
Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):220-228. PubMed ID: 30883392
[TBL] [Abstract][Full Text] [Related]
36. Effects of opiate drugs on Fas-associated protein with death domain (FADD) and effector caspases in the rat brain: regulation by the ERK1/2 MAP kinase pathway.
García-Fuster MJ; Miralles A; García-Sevilla JA
Neuropsychopharmacology; 2007 Feb; 32(2):399-411. PubMed ID: 16482086
[TBL] [Abstract][Full Text] [Related]
37. The role of corticotropin-releasing factor in drug addiction.
Sarnyai Z; Shaham Y; Heinrichs SC
Pharmacol Rev; 2001 Jun; 53(2):209-43. PubMed ID: 11356984
[TBL] [Abstract][Full Text] [Related]
38. Modulation by catecholamine of hypothalamus-pituitary-adrenocortical (HPA) axis activity in morphine-tolerance and withdrawal.
Martinez-Piñero MG; Milanes MV; Vargas ML
Gen Pharmacol; 1994 Jan; 25(1):187-92. PubMed ID: 8026704
[TBL] [Abstract][Full Text] [Related]
39. Time-dependent alterations in mRNA expression of brain neuropeptides regulating energy balance and hypothalamo-pituitary-adrenal activity after withdrawal from intermittent morphine treatment.
Houshyar H; Manalo S; Dallman MF
J Neurosci; 2004 Oct; 24(42):9414-24. PubMed ID: 15496677
[TBL] [Abstract][Full Text] [Related]
40. Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal.
Zhou Y; Spangler R; LaForge KS; Maggos CE; Ho A; Kreek MJ
J Pharmacol Exp Ther; 1996 Oct; 279(1):351-8. PubMed ID: 8859013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
